Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.65 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.65 |
| ▸ | MGLL | Q99685 | 15/20 | 0.59 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.54 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.54 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20897546 | 1.00 | HTR3A (0.65) | HTR3AHRH4MGLLHCRTR1HCRTR2 | |
| SCHEMBL26170030 | 0.88 | NAMPT (0.51) | HTR3AHRH4MGLLNAMPTKCNH2 | |
| SCHEMBL20897590 | 0.88 | MGLL (0.54) | HTR3AHRH4MGLLHCRTR1HCRTR2 | |
| SCHEMBL20897769 | 0.85 | HTR3A (0.62) | HTR3AMGLL | |
| SCHEMBL22442389 | 0.84 | HTR3A (0.73) | HTR3AHRH4MGLLHCRTR1HCRTR2 | |
| SCHEMBL1777998 | 0.84 | NAMPT (0.55) | HTR3AHRH4NAMPTKCNH2 | |
| SCHEMBL25220184 | 0.81 | KCNH2 (0.50) | MGLLNAMPTKCNH2 | |
| SCHEMBL29784222 | 0.81 | MGLL (0.53) | MGLLHCRTR1HCRTR2NAMPTKCNH2 | |
| SCHEMBL20898197 | 0.81 | MGLL (0.53) | MGLLHCRTR1HCRTR2NAMPTKCNH2 | |
| SCHEMBL20897501 | 0.80 | MGLL (0.54) | HTR3AMGLLNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2022-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | MAGI3, PYM1, MAG | HTR3A 2659/4885HRH4 1302/4885MGLL 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.